Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 2% Improvement Relative Risk Ventilation 5% ICU admission 9% Oxygen therapy 3% c19early.org/cbd Shover et al. Cannabidiol for COVID-19 Prophylaxis Favors cannabidiol Favors control
Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis
Shover et al., Journal of Cannabis Research, doi:10.1186/s42238-022-00152-x
5 Aug 2022    Source   PDF   Share   Tweet
Retrospective 1,831 hospitalized COVID-19 patients in the USA, showing lower mechanical ventilation and ICU admission, but no significant difference in mortality.
risk of death, 1.8% lower, RR 0.98, p = 0.56, treatment 3 of 69 (4.3%), control 199 of 1,762 (11.3%), odds ratio converted to relative risk, propensity score matching.
risk of mechanical ventilation, 5.1% lower, RR 0.95, p = 0.02, treatment 3 of 69 (4.3%), control 292 of 1,762 (16.6%), NNT 8.2, odds ratio converted to relative risk, propensity score matching.
risk of ICU admission, 8.6% lower, RR 0.91, p = 0.02, treatment 8 of 69 (11.6%), control 543 of 1,762 (30.8%), NNT 5.2, odds ratio converted to relative risk, propensity score matching.
risk of oxygen therapy, 2.6% lower, RR 0.97, p = 0.27, treatment 35 of 69 (50.7%), control 1,417 of 1,762 (80.4%), NNT 3.4, odds ratio converted to relative risk, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shover et al., 5 Aug 2022, retrospective, USA, peer-reviewed, 7 authors, study period 12 February, 2020 - 27 February, 2021.
Contact: ibarjaktarevic@mednet.ucla.edu (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit